Literature DB >> 20836750

Interferons as potential adjuvants in prophylactic vaccines.

Roberta Toporovski1, Matthew P Morrow, David B Weiner.   

Abstract

IMPORTANCE OF THE FIELD: Vaccines are still one of the best approaches to manage infectious diseases. Despite the advances in drug therapies, prophylactic medicine is still more cost efficient and minimizes the burden in the heath system. Despite all the research in vaccine development, many infectious diseases are still without an effective vaccine. The use of adjuvants in vaccines has been one successful strategy to increase efficacy. IFNs are widely expressed cytokines that have potent antiviral effects. These cytokines are the first line of defense against viral infections and have important roles in immuno surveillance for malignant cells. One of the most promising uses of IFNs is as adjuvants that are co-applied with antigen in vaccines. AREAS COVERED IN THIS REVIEW: In this review, a cumulative analysis of many of the studies that have used IFN-α, -β, -γ and -λ as adjuvants between 1987 and the present suggests that many do possess the capacity to serve as potent immunoadjuvants for vaccination. WHAT THE READER WILL GAIN: This review provides a very large collection of studies involving all types of IFNs used as adjuvants in vaccines using different vaccination strategies and various animal models. TAKE HOME MESSAGE: It is clear that the use of IFNs not only improved the efficacy and safety of most vaccines, but also had important immunomodulatory effect directing T(H)1 immune responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20836750     DOI: 10.1517/14712598.2010.521495

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  10 in total

Review 1.  The dawn of vaccines for cancer prevention.

Authors:  Olivera J Finn
Journal:  Nat Rev Immunol       Date:  2017-12-27       Impact factor: 53.106

2.  Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.

Authors:  Svitlana P Grekova; Marc Aprahamian; Laurent Daeffler; Barbara Leuchs; Assia Angelova; Thomas Giese; Angel Galabov; Anette Heller; Nathalia A Giese; Jean Rommelaere; Zahari Raykov
Journal:  Cancer Biol Ther       Date:  2011-11-15       Impact factor: 4.742

3.  A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant.

Authors:  L Martínez-Gil; P H Goff; R Hai; A García-Sastre; M L Shaw; P Palese
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

4.  Identification of small molecules with type I interferon inducing properties by high-throughput screening.

Authors:  Luis Martínez-Gil; Juan Ayllon; Mila Brum Ortigoza; Adolfo García-Sastre; Megan L Shaw; Peter Palese
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

5.  Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity.

Authors:  Irina Margine; Luis Martinez-Gil; Yi-Ying Chou; Florian Krammer
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

6.  Tubular immunostimulating complex based on cucumarioside A2-2 and monogalactosyldiacylglycerol from marine macrophytes.

Authors:  Eduard Y Kostetsky; Nina M Sanina; Andrey N Mazeika; Alexander V Tsybulsky; Natalia S Vorobyeva; Valery L Shnyrov
Journal:  J Nanobiotechnology       Date:  2011-09-02       Impact factor: 10.435

7.  Optimization of Fermentation Conditions for Recombinant Human Interferon Beta Production by Escherichia coli Using the Response Surface Methodology.

Authors:  Mohammad Hossein Morowvat; Valiollah Babaeipour; Hamid Rajabi Memari; Hossein Vahidi
Journal:  Jundishapur J Microbiol       Date:  2015-04-18       Impact factor: 0.747

8.  IL-28B is a key regulator of B- and T-cell vaccine responses against influenza.

Authors:  Adrian Egli; Deanna M Santer; Daire O'Shea; Khaled Barakat; Mohammedyaseen Syedbasha; Madeleine Vollmer; Aliyah Baluch; Rakesh Bhat; Jody Groenendyk; Michael A Joyce; Luiz F Lisboa; Brad S Thomas; Manuel Battegay; Nina Khanna; Thomas Mueller; D Lorne J Tyrrell; Michael Houghton; Atul Humar; Deepali Kumar
Journal:  PLoS Pathog       Date:  2014-12-11       Impact factor: 6.823

Review 9.  Interferons as therapeutic agents for infectious diseases.

Authors:  Scott J Bergman; McKenzie C Ferguson; Cathy Santanello
Journal:  Infect Dis Clin North Am       Date:  2011-12       Impact factor: 5.982

Review 10.  MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity.

Authors:  Kamal U Saikh
Journal:  Immunol Res       Date:  2021-04-08       Impact factor: 2.829

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.